Which is better, oral or injectable estradiol?

Both can hit target levels for most users. Injection VTE risk is near baseline; oral is 2-4x baseline. International guidelines preferentially recommend non-oral routes (injection / gel / patch) for users aged 40+, smokers, those who are obese, or those with clotting disorders. Young, healthy users may choose either.

Do I have to inject estradiol myself?

Hospitals in mainland China usually do not provide routine HRT IM injection services; most users self-inject or have a friend assist. The learning curve is moderate, but for the first injection you should have someone present or video guidance, plus disinfection supplies and a plan for vasovagal reactions.

Will switching from oral to injection cause a rebound?

Short-term transitional fluctuation is possible: oral plasma levels clear within 24 hours after the last dose, while injections take 2-3 doses to reach steady state. Overlap for 1-2 weeks during the switch and confirm steady state with bloodwork before fully discontinuing oral.

How large is the VTE risk from oral estradiol?

The absolute risk remains low: baseline VTE in young, healthy MTF users is ~1-2/1000 person-years; oral estradiol raises it to ~3-6/1000 person-years. Injection/transdermal is roughly baseline. Smoking, obesity, and age stack the absolute risk substantially.

Does sublingual count as oral or transdermal?

It sits between the two. Sublingual mucosal absorption partially bypasses hepatic first-pass, so VTE risk may be lower than swallowed oral, but the evidence is weaker than for injection/transdermal. Plasma levels show high peaks and deep troughs, less stable than patch/gel/injection.

Oral vs Injectable Estradiol: Clinical Comparison of Routes

Oral estradiol (Progynova / estradiol valerate tablets) and intramuscular estradiol valerate (EV) injection are the two most common E2 routes in the Chinese-speaking MTF community. This page compares pharmacokinetics, safety, and practical barriers, without giving a universal recommendation.

If your situation is →	Recommended choice
You want the lowest VTE risk / age ≥40 / smoker / BMI>30	Injectable EV · bypasses hepatic first-pass, RR ≈ 1
Needle-phobic / chaotic schedule / unwilling to learn the procedure	Oral Progynova · zero learning curve
History of VTE / migraine with aura / Factor V Leiden	Injectable EV (or transdermal) · oral contraindicated
Easy access in mainland China + low effort	Oral Progynova · stocked in OB/GYN
Monotherapy goal (no antiandrogen)	Injectable EV · ~82% reach T <50 ng/dL
Inconsistent injection intervals / want intra-day stability	Oral BID · injection peak-to-trough ~3-4:1
Pregnancy / breastfeeding / under 18	Neither recommended; please see a clinician

Not sure? Read on for the detailed comparison, or use the risk self-screener for help.

At a Glance

Dimension	Oral (Progynova)	Injection (estradiol valerate, EV)
Hepatic first-pass	Yes (passes through)	No (bypassed)
VTE risk	2-4x baseline	~baseline
Dosing frequency	1-3 times per day	Every 5-10 days
Plasma-level stability	Intra-day peaks/troughs	Inter-dose fluctuation
Onset	Hours to peak	Peaks in 24-48 hours
Evidence level	A	A
Availability in mainland China	Prescription-only; common in OB/GYN and endocrinology	Prescription-only; some hospitals reluctant to prescribe
Monthly cost	~20-60 RMB	~30-100 RMB
Practical barrier	Zero	Self-IM learning curve

Pharmacokinetics

Oral: hepatic first-pass shapes the curve

Oral estradiol or estradiol valerate is absorbed in the small intestine, enters the liver via the portal vein, and loses 50-70% to first-pass metabolism^[13]. The systemic effective dose is only 30-50% of the swallowed dose, and the liver is “soaked” in high concentrations of E2/E1.

Oral 2-4 mg → plasma peak ~50-150 pg/mL, falls back after 4-8 hours
Half-life ~12-14 hours (as E2), but E1/E2 ratio is skewed high
Hepatic production of SHBG, clotting factors, and CRP rises → elevated VTE / cholestasis risk^[2]

Injection: muscular slow-release, flatter curve

After IM EV injection, the oily vehicle forms a depot in the muscle and the ester bond hydrolyzes slowly to release E2^[1]:

4 mg EV IM → peaks 24-48 hours later at ~300-600 pg/mL, then declines exponentially
Half-life ~4-5 days; falls to 100-150 pg/mL by 5-7 days
Completely bypasses hepatic first-pass; coagulation effects approximate physiological estradiol

VTE Risk Comparison

Based on large MTF cohorts and postmenopausal HRT studies^[2]^[3]:

Route	Relative VTE risk vs baseline
Oral estradiol	2-4x
Conjugated equine estrogens (CEE, obsolete)	4-6x
Sublingual	Possibly 1.5-3x (limited evidence)
Transdermal gel / patch	1x (baseline)
IM estradiol valerate	1x (baseline)

Absolute risk is still low: baseline VTE in young, healthy MTF users is ~1-2/1000 person-years. Smoking + obesity + age >40 stack to substantially raise absolute risk.

Guideline position^[3]^[7]:

Age ≥40 + any risk factor → prefer non-oral
History of VTE → avoid oral; prefer transdermal/injection + anticoagulation evaluation
2-4 weeks pre-surgery → switch to transdermal or pause

Plasma Stability

Oral vs intramuscular E2 plasma-level comparison waveform: oral twice daily shows intra-day peak-trough fluctuation (100-400 pg/mL); weekly injection shows a slow decline from peak ~600 pg/mL to trough ~150 pg/mL across the week

Route	Intra-day variation	Inter-day variation	Symptom impact
Oral once daily	Peak/trough ~3:1	Small	Mood swings · cyclical edema feeling
Oral twice daily	Peak/trough ~2:1	Small	More even
Injection every 7 days	None	Peak/trough ~3-4:1	”Post-injection high” for a few days
Injection every 5 days	None	Peak/trough ~2:1	Better steady state
Patch / gel	Small	Small	Most stable

Selection logic: users seeking stable mood and embodiment prefer patch / gel / short-interval injection; users sensitive to dose flexibility prefer oral.

Onset and Switching

Oral onset

Peak at 2-4 hours after dose; tissue responses (breast development, skin changes) appear at 1-3 months
Steady-state T suppression ~4-8 weeks (with antiandrogen)

Injection onset

First injection peaks in 24-48 hours but cannot reach steady state
After 2-3 doses (~10-20 days) approaches steady state
During transition, overlap is recommended: keep oral going for 1-2 weeks before the first injection, then taper

Switching between routes

Oral → injection:

Calculate equivalent dose: oral 2-4 mg/day ≈ EV 4-8 mg every 7 days
Maintain oral for 2-4 days after the first injection, then taper
Check trough E2 at 4-6 weeks post-injection to confirm steady state

Injection → oral:

Stop the last injection; wait 5-7 days for plasma levels to fall
Start oral; initial dose is often 1-1.5x the steady-state injection equivalent (to compensate for hepatic first-pass)
Re-check bloodwork at 2-4 weeks for adjustment

Practical Barriers

Oral

Zero barrier; just take on schedule
Note: Progynova is estradiol valerate 2 mg per tablet, equivalent to “estradiol 2 mg” — no conversion needed
Missed dose: take it within 12 hours; skip if more than 12 hours late

Self-injection

Oily IM injection: 23G 1-1.5 inch needle (~25-38 mm), 21G for drawing
Injection sites: dorsogluteal (upper outer quadrant), anterior lateral thigh, deltoid (small volumes)
Disinfection: 70% alcohol; wipe vial stopper for 30 seconds, swab injection site in a circular motion
Technique: bleed air bubbles, push slowly (10-30 seconds), press the site for 30 seconds after withdrawal

Subcutaneous (SC) alternative

Oily EV can be injected subcutaneously (abdomen, anterior thigh) with less pain and a slightly longer half-life. Needle 25G × 5/8 inch (16 mm). Evidence is moderate; some guidelines now accept it^[1].

Availability in Mainland China

Channel	Oral (Progynova)	Injection (EV)
OB/GYN	Stocked, easy to prescribe	Some hospitals decline
Endocrinology	Easy	Depends on physician attitude
Reproductive medicine	Very easy	Common in ovarian-stimulation protocols
Psychiatry (trans clinic)	Available	Available
Cost	20 mg × 30 tabs ~40 RMB	5 mg/mL × 10 amps ~60-100 RMB
Insurance	Partial reimbursement	Partial reimbursement

How to Choose (Clinical Decision Framework)

Prefer oral when:

Young, no VTE risk factors, unwilling to learn IM injection
Injection access is difficult or physicians refuse to prescribe
Short-term bridge that will switch in a few months
High acceptance of “daily medication” form

Prefer injection when:

Age ≥40 or VTE risk factors (smoking/obesity/family history)
Inconsistent oral absorption (GI surgery history, IBD)
Seeking a flatter plasma profile
Willing to learn self-injection

Prefer patch / gel (not compared on this page, but often optimal):

VTE history or high risk
Want to avoid needles entirely
Sensitive to fine dose adjustment